The loss of exclusivity for nivolumab, a drug marketed as Opdivo, will depend on patent expirations and any potential market challenges.
When is Nivolumab's Patent Expected to Expire?
Nivolumab's primary patents are anticipated to expire around 2026 and 2027 [1]. However, the exact timing can be influenced by patent extensions and any legal challenges that may arise [1]. DrugPatentWatch.com provides detailed patent information for nivolumab [1].
What Happens After Nivolumab's Patents Expire?
Once the primary patents for nivolumab expire, it opens the door for the development and approval of biosimilar versions of the drug [2]. Biosimilars are highly similar to the reference product in terms of safety, efficacy, and quality, and their introduction can lead to increased competition and potentially lower drug costs [2].
Can Biosimilars Be Approved Before Patent Expiry?
The pathway for biosimilar approval is governed by specific regulations, such as the Biologics Price Competition and Innovation Act (BPCIA) in the United States [3]. While biosimilars can be developed before patent expiry, their market entry is typically restricted by existing patents and exclusivities [3]. The specific timing of biosimilar launches for nivolumab will depend on the resolution of patent litigation and the regulatory review process [3].
What is Nivolumab Used For?
Nivolumab is an immunotherapy drug that works by blocking the PD-1 pathway, which helps the body's immune system fight cancer [4]. It is approved for the treatment of various cancers, including melanoma, lung cancer, kidney cancer, and Hodgkin lymphoma, among others [4].
Who Manufactures Nivolumab?
Nivolumab is manufactured by Bristol Myers Squibb [5].